Abstract: A display device includes first and second light emitting regions; first and second pixel electrodes in the first and second light emitting regions, respectively; a first organic layer in the first light emitting region, including first and second light emitting layers; a second organic layer in the second light emitting region, including a third light emitting layer; a common electrode on the first and second organic layers; a wavelength conversion pattern on the common electrode, overlapping the first organic layer, and wavelength-converting light of a first color into light of a second color, different from the first color; and a light transmitting pattern on the common electrode, overlapping the second organic layer. The third light emitting layer and one of the first and second light emitting layers emit light of the first color, and another one of the first and second light emitting layers emits light of the second color.

Abstract: Provided in the present invention is a novel use of composition containing a neoagarooligosaccharide mixture as an active ingredient. The neoagarooligosaccharide mixture and the like as an active ingredient of the composition according to the present invention can reduce the expression of RANKL, an osteoclast inducer, or IL-6, an inflammatory cytokine, and effectively inhibit differentiation of monocytes into osteoclasts. Thus, the composition according to the present invention may be used as a medicine or functional food for preventing, alleviating, or treating arthritis (especially rheumatoid arthritis). Further, the active ingredient of the composition according to the present invention can be obtained by an enzyme reaction between a readily available substrate such as agar or agarose and DagA as a beta-agarase derived from Streptomyces coelicolor. Thus, it can be produced at a relatively low cost and can easily be ingested by anyone because it has no side effects.

Abstract: The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-? and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII.

Abstract: Provided in the present invention is a composition having a novel use and containing a neoagarooligosaccharide mixture as an active ingredient. According to the present invention, a neoagarooligosaccharide mixture, which is the active ingredient of the composition according to the present invention, and the like can reduce the expression of RANKL, which is an osteoclast inducer, and effectively inhibit the differentiation of mononuclear cells into osteoclasts. Therefore, the composition according to the present invention can be used as a medicine or functional food for preventing, alleviating, or treating arthritis (especially rheumatoid arthritis) or osteoporosis.

Abstract: The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-? and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII.

Abstract: The present invention relates to a method and a kit for monitoring an immune status after transplant. The kit for monitoring an immune status after transplant and the method for monitoring an immune status of an individual after transplant as provided in the present invention make it easy and accurate to determine an immune status in the individual after transplant and thus have an effect of reducing overuse of an immunosuppressive agent prescribed after transplant and also have an effect of conveniently managing an immune status of each patient.

Abstract: The present invention relates to a method and a kit for monitoring an immune status after transplant. The kit for monitoring an immune status after transplant and the method for monitoring an immune status of an individual after transplant as provided in the present invention make it easy and accurate to determine an immune status in the individual after transplant and thus have an effect of reducing overuse of an immunosuppressive agent prescribed after transplant and also have an effect of conveniently managing an immune status of each patient.